The Risks of Femoral Localized Periosteal Thickening in Patients with Autoimmune Inflammatory Rheumatic Diseases.
Hiroe SatoNaoki KondoChinatsu TakaiYoichi KurosawaEriko HasegawaAyako WakamatsuDaisuke KobayashiTakeshi NakatsueAsami AbeJunichiro James KazamaTakeshi KurodaSatoshi ItoHajime IshikawaNaoto EndoIchiei NaritaPublished in: Modern rheumatology (2022)
LPT in Japanese patients with AIRDs was associated with BP and glucocorticoid treatment rather than underlying AIRDs. When a PSL dose ≥ 5.5 mg/day is required long-term (typically combined with long-term BP treatment [≥ 5 years]), clinicians need to pay particular attention in case LPT and AFF, as well as glucocorticoid-induced osteoporosis.